Roger Jeffs, Ph.D.
Roger Jeffs retired as President and co-CEO at United Therapeutics in 2016 after a successful 18-year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as Director of Research, Development, and Medical, and served as the company’s President and Chief Operating Officer from 2001 to 2014 and President & co-CEO from 2015-2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs previously served on the Board of Directors for United Therapeutics, Dova Pharmaceuticals, and Sangamo Therapeutics and currently serves on the Boards of Albireo Pharma, and Axsome Therapeutics.